Leerink reiterates Eli Lilly stock rating on obesity drug approval

FDA approved Eli Lilly's oral obesity drug orforglipron (Foundayo) and will offer it via LillyDirect starting April 6 with self-pay pricing of $149–$349/month and loyalty discounts to $299 for certain refills; highest-dose trial patients lost an average 27.3 lbs. Lilly reported revenue up ~45% over the last 12 months (as of Q4 2025) and has a market cap of $858B; the company also agreed to acquire Centessa Pharmaceuticals for ~ $7.8B. Multiple brokers reiterated bullish ratings and high price targets (Leerink $1,296, Truist $1,281, Barclays $1,350, BMO $1,300), and InvestingPro flags the stock below fair value with an 83% gross margin — all indicating meaningful upside for the stock and sector.

Analysis

The market reaction likely underweights the immediate commercial complexity: converting demand into durable, high-margin revenue requires moving patients through payer formularies, adherence programs, and specialty pharmacy logistics — expect realized net price to sit materially below headline cash prices once PBM rebates and loyalty discounts are normalized. Payers historically extract 20–40% concessions on newly disruptive specialty therapies within 6–12 months; if that pattern repeats, gross margin upside will be smaller and front-loaded cash pay uptake will set the adoption curve rather than long-term net revenue.

Second-order competitive effects will accelerate vertical repositioning across the supply chain. Large integrated distributors, specialty pharmacies, and PBMs gain incremental negotiating leverage as manufacturers chase scale; meanwhile incumbents with injectable franchises face both share erosion and a forced shift toward outcomes- and cost-per-pound metrics in contract renewals, which will compress realized ASPs across the class over 12–24 months.

Key risks and catalysts: near-term uptake metrics (first 3 months of scripts, refill rates at 45 days) and payer formulary decisions over the next 3–9 months are the primary value inflection points. Over 1–3 years the biggest reversal drivers are (1) aggressive payer rebateing/formulary exclusions that cut realized price, (2) manufacturing or distribution bottlenecks that delay scale, and (3) any safety signals or regulatory label changes that limit indication breadth. The recent small-cap acquisition adds pipeline optionality but introduces integration execution risk and capital allocation scrutiny that will matter to long-term returns.

Key Decisions for Investors

• Long LLY (unhedged equity): establish a core position over 1–3 weeks on weakness. Timeframe 6–12 months. R/R: target +25–35% upside if adoption and payer access track, downside ~15% on rapid rebate compression or safety headlines; size to 2–4% portfolio weight.
• LLY options (directional but defined risk): buy 9-month calls ~10% OTM (or a 9-month 10/20% call spread funded by a 3-month call sale). Timeframe 3–9 months to capture early uptake and formulary signals. R/R: asymmetric — limited premium risk for 2–4x upside if adoption accelerates; hedge by selling near-term calls to fund longer-dated exposure.
• Pair trade (relative value): long LLY / short NVO equal-dollar sized to neutralize market beta. Timeframe 6–12 months. Rationale: capture potential share shift to an oral offering and relative re-rating; risk if Novo sustains volume/pricing leadership and widens its margin gap. Target relative return 10–20% with stop if spread moves >15% adverse.
• Merger-arbitrage on CNTA (deal-arb conditional): go long CNTA only if spread to bid/offer >3% with strict position sizing. Timeframe until deal close (3–9 months). R/R: small stable yield if deal closes; tail risk is deal renegotiation/regulatory friction — hedgeable by sizing and CDS if available.